...
首页> 外文期刊>World Journal of Gastroenterology >Serum concentrations of insulin-like growth factor-binding protein 5 in Crohn’s disease
【24h】

Serum concentrations of insulin-like growth factor-binding protein 5 in Crohn’s disease

机译:克罗恩病患者血清中胰岛素样生长因子结合蛋白5的浓度

获取原文
           

摘要

AIM: To investigate serum insulin-like growth factor-binding protein 5 (IGFBP-5) levels and intestinal IGFBP-5 expression in patients with Crohn’s disease (CD). METHODS: We analyzed the serum concentrations and intestinal expression of IGFBP-5 in 42 patients with CD, of whom 26 had endoscopically or radiologically proven stricture formation. Nine of the 42 patients had active disease, with a Crohn’s disease activity index > 150. Serum IGFBP-5 levels were analyzed in 20 healthy controls matched by sex and age to the CD patients. Serum IGFBP-5 was measured using an enzyme-linked immunosorbent assay. Intestinal tissue was obtained from patients through endoscopic biopsies. IGFBP-5 expression was detected using immunohistochemistry and was scored semiquantitatively. RESULTS: The median serum IGFBP-5 concentrations of CD patients were significantly lower compared with healthy controls [median 7.2 (IQR: 5.5-11.3) ng/mL vs 11.3 (8.0-44.6) ng/mL, P vs 7.8 (5.3-10.1) ng/mL, P = 0.815]. The serum IGFBP-5 levels were not significantly different between patients with active disease and inactive disease [7.2 (6.5-7.6) ng/mL vs 7.2 (5.5-11.3) ng/mL, P = 0.890]. However, a significant correlation was observed between serum IGFBP-5 levels and platelet count (PLT) (r = 0.319, P = 0.0395). No significant correlation was found between tissue IGFBP-5 immunohistochemical staining intensity scores and serum IGFBP-5 levels. No significant difference was found when comparing the serum IGFBP-5 levels among the patients with different tissue IGFBP-5 staining scores (absent/very weak, weak, moderate or strong). There was a significant correlation between tissue IGFBP-5 staining scores and white blood cell count (r = 0.391, P = 0.01) and PLT (r = 0.356, P = 0.021). CONCLUSION: Our results indicate that serum IGFBP-5 concentrations were lower in CD patients compared to healthy controls regardless of disease activity or the presence of stricture formation.
机译:目的:研究克罗恩病(CD)患者的血清胰岛素样生长因子结合蛋白5(IGFBP-5)水平和肠道IGFBP-5表达。方法:我们分析了42例CD患者的IGFBP-5的血清浓度和肠道表达,其中26例经内镜或放射学证实狭窄。 42例患者中有9例患有活动性疾病,克罗恩病活动指数>150。分析了20名健康对照者的血清IGFBP-5水平,并按性别和年龄与CD患者进行了比较。使用酶联免疫吸附测定法测量血清IGFBP-5。通过内窥镜活检从患者获得肠组织。使用免疫组织化学检测IGFBP-5表达,并进行半定量评分。结果:与健康对照组相比,CD患者的血清IGFBP-5的中位数浓度显着降低[中位值7.2(IQR:5.5-11.3)ng / mL vs 11.3(8.0-44.6)ng / mL,P vs 7.8(5.3-10.1) )ng / mL,P = 0.815]。患有活动性疾病和非活动性疾病的患者的血清IGFBP-5水平无显着差异[7.2(6.5-7.6)ng / mL与7.2(5.5-11.3)ng / mL,P = 0.890]。然而,在血清IGFBP-5水平和血小板计数(PLT)之间观察到显着相关性(r = 0.319,P = 0.0395)。在组织IGFBP-5免疫组织化学染色强度评分与血清IGFBP-5水平之间未发现显着相关性。比较具有不同组织IGFBP-5染色评分(无/非常弱,弱,中或强)的患者的血清IGFBP-5水平时,没有发现显着差异。组织IGFBP-5染色评分与白细胞计数(r = 0.391,P = 0.01)和PLT(r = 0.356,P = 0.021)之间存在显着相关性。结论:我们的结果表明,无论疾病活动或狭窄形成的存在,CD患者的血清IGFBP-5浓度均低于健康对照组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号